Secukinumab: In psoriasis and beyond

被引：0

作者：

Bubna, Aditya K. ^{[1
]}

Viplav, Vinayak ^{[1
]}

机构：

[1] Katihar Med Coll, Dept Dermatol, Katihar 854106, Bihar, India

来源：

JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY | 2025年 / 22卷 / 01期

关键词：

hidradenitis suppurativa; off-label dermatologic indications; psoriasis; secukinumab; ORAL LICHEN-PLANUS; HIDRADENITIS SUPPURATIVA; PALMOPLANTAR PSORIASIS; PYODERMA-GANGRENOSUM; CONTROLLED-TRIAL; DOUBLE-BLIND; TH17; EFFICACY; THERAPY; SAFETY;

D O I：

10.4103/jewd.jewd_80_23

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (>= 6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Beh & ccedil;et's disease. This review will throw light on secukinumab's utility in psoriasis, as well as other dermatologic conditions.

引用

页码：1 / 12

页数：12

共 98 条

[1]

Aboobacker S., 2023, Secukinumab. Updated 2023 Jun 20. In: StatPearls Internet

[2] Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment [J].

Alavi, Afsaneh ;

French, Lars E. ;

Davis, Mark D. ;

Brassard, Alain ;

Kirsner, Robert S. .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (03) :355-372

[3] Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) [J].

Bagel, J. ;

Blauvelt, A. ;

Nia, J. ;

Hashim, P. ;

Patekar, M. ;

de Vera, A. ;

Ahmad, K. ;

Paguet, B. ;

Xia, S. ;

Muscianisi, E. ;

Lebwohl, M. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) :135-142

[4] Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis [J].

Blair, Hannah A. .

PEDIATRIC DRUGS, 2021, 23 (06) :601-608

[5] Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].

Blauvelt, A. ;

Prinz, J. C. ;

Gottlieb, A. B. ;

Kingo, K. ;

Sofen, H. ;

Ruer-Mulard, M. ;

Singh, V. ;

Pathan, R. ;

Papavassilis, C. ;

Cooper, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493

[6] Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial [J].

Bodemer, C. ;

Kaszuba, A. ;

Kingo, K. ;

Tsianakas, A. ;

Morita, A. ;

Rivas, E. ;

Papanastasiou, P. ;

Keefe, D. ;

Patekar, M. ;

Charef, P. ;

Zhang, L. ;

Cafoncelli, S. ;

Papavassilis, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) :938-947

[7]

Bonomo L, 2018, CUTIS, V101, P367

[8] Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis [J].

Boudreaux, Blake W. ;

Pincelli, Thais P. ;

Bhullar, Puneet K. ;

Patel, Meera H. ;

Brumfiel, Caitlin M. ;

Li, Xing ;

Heckman, Michael G. ;

Pittelkow, Mark R. ;

Mangold, Aaron R. ;

Sluzevich, Jason C. .

BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (05) :650-658

[9] Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients [J].

Bruin, Gerard ;

Hockey, Hans-Ulrich P. ;

La Stella, Phillip ;

Sigurgeirsson, Bardur ;

Fu, Rong ;

Patekar, Manmath ;

Charef, Pascal ;

Woessner, Ralph ;

Boutouyrie-Dumont, Bruno .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (02) :338-351

[10]

Cada Dennis J, 2015, Hosp Pharm, V50, P714, DOI 10.1310/hpj5008-714

← 1 2 3 4 5 6 7 8 9 10 →